This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Inhaled fentanyl
Description: Fentanyl TAIFUN is an inhaled formulation of fentanyl, an opioid agonist, using LAB's TAIFUN, a dry powder pulmonary delivery system.
Deal Structure: On January 13, 2006, LAB International announced it had entered into a licensing and development agreement with Teikoku Seiyaku for the development of Fentanyl TAIFUN in Japan. Under the terms of the agreement, LAB will receive a signing fee, development milestones payments and R&D reimbursements for development activities conducted by LAB in support of the development in Japan. In addition, Teikoku Seiyaku will pay LAB royalties on sales and manufacturing revenues for supplying the finished product.
On June 21, 2007, LAB International announced that it had signed a licensing and development agreement with Janssen Pharmaceutica NV for the development of Fentanyl TAIFUN in Europe. Under the terms of the agreement, LAB will receive a signing fee of US $10.8 million ( 8.0 million), up to US $33.6 million ( 25.0 million) in development and regulatory milestones as well as payments of commercial sales milestones. LAB could receive significant royalty income on sales of the product as...See full deal structure in Biomedtracker
Partners: Teikoku Seiyaku Johnson & Johnson
Fentanyl TAIFUN News
Additional information available to subscribers only: